Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gynecologic Oncology

• Publication date

  2014-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2014.04.044PMID 24786638PMCID PMC4065804
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2014

  2014cited by this paper
• Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function

  2014cited by this paper
• Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression

  2013influential reference
• HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.

  2013cited by this paper
• RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

  2013cited by this paper
• Merlin: the wizard requires protein stability to function as a tumor suppressor.

  2012cited by this paper
• Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

  2012cited by this paper
• Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features

  2012cited by this paper
• First-line chemotherapy in epithelial ovarian cancer.

  2012cited by this paper
• Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.

  2012cited by this paper
• The changing view of high-grade serous ovarian cancer.

  2012cited by this paper
• Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients.

  2012cited by this paper
• Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features.

  2012cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Rethinking ovarian cancer: recommendations for improving outcomes

  2011cited by this paper
• Molecular Targeted Therapy in Ovarian Cancer

  2011cited by this paper
• PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments

  2010cited by this paper
• Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions

  2010cited by this paper
• Development of a syngeneic mouse model of epithelial ovarian cancer

  2010cited by this paper
• Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer

  2010cited by this paper
• The genesis and evolution of high-grade serous ovarian cancer

  2010cited by this paper
• Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models

  2010cited by this paper
• The biology of ovarian cancer: new opportunities for translation

  2009cited by this paper
• Targeted therapies: a new generation of cancer treatments.

  2008cited by this paper
• Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.

  2008cited by this paper
• Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.

  2008cited by this paper
• Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

  2007cited by this paper
• Integrin-regulated FAK-Src signaling in normal and cancer cells.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK

  2006cited by this paper
• Focal Adhesion Kinase Silencing Augments Docetaxel-Mediated Apoptosis in Ovarian Cancer Cells

  2005cited by this paper
• Focal adhesion kinase: in command and control of cell motility

  2005cited by this paper
• Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.

  2004cited by this paper
• Regulation of uncoupling protein-2 mRNA in L6 myotubules

  2002cited by this paper
• First line Chemotherapy for Epithelial Ovarian Cancer

  2001cited by this paper
• Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids.

  2001cited by this paper
• Development of a syngeneic mouse model for events related to ovarian cancer.

  2000cited by this paper
• Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma

  1999cited by this paper
• Cancer statistics

  1989cited by this paper

• Nf2-FAK signaling axis is critical for cranial bone ossification and regeneration

  2025cites this paper
• Context-specific targeting of focal adhesion kinase in brain tumors: lessons from glioblastoma and neurofibromatosis type 2-mutant meningioma

  2025cites this paper
• FGFR2-regulated cytoskeletal rearrangement disturbs autophagy flux induced by polystyrene nanoplastics.

  2025cites this paper
• TNIK in disease: from molecular insights to therapeutic prospects

  2024cites this paper
• Zebrafish patient-derived xenograft system for predicting carboplatin resistance and metastasis of ovarian cancer.

  2024cites this paper
• Chemotherapy in the structure of complex treatment of patients with recurrent intracranial meningiomas

  2024cites this paper
• Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors

  2023cites this paper
• Novel Medical Therapies in Meningiomas.

  2023cites this paper
• FAK-mediated phosphorylation at Y464 regulates p85β nuclear translocation to promote tumorigenesis of ccRCC by repressing RB1 expression.

  2023cites this paper
• GBP5 and ACSS3: two potential biomarkers of high-grade ovarian cancer identified through downstream analysis of microarray data

  2022cites this paper
• Identification of defactinib derivatives targeting focal adhesion kinase using ensemble docking, molecular dynamics simulations and binding free energy calculations

  2022cites this paper
• Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase

  2022cites this paper
• Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy

  2022cites this paper
• Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma

  2022cites this paper
• Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?

  2021cites this paper
• Crispr/Cas-based modeling of NF2 loss in meningioma cells.

  2021cites this paper
• Current experimental therapies for atypical and malignant meningiomas

  2021cites this paper
• Promising Investigational New Drugs for Mesothelioma: What Is the Next Stage of the Treatment for Advanced Mesothelioma?

  2021cites this paper
• 10 Management of Benign Skull Base Tumors in Neuro-oncology: Systemic Cytotoxic and Targeted Therapies Systemic cytotoxic and targeted therapies Benign skull base tumors in neuro-oncology

  2021cites this paper
• The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)

  2021cites this paper
• Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer

  2021cites this paper
• Merlin functions as a critical regulator in Staphylococcus aureus‐induced osteomyelitis

  2021cites this paper
• EANO guideline on the diagnosis and management of meningiomas.

  2021cites this paper
• T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

  2020cites this paper
• BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways

  2020cites this paper
• Medical management of meningiomas.

  2020cites this paper
• Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins

  2019cites this paper
• Advances in multidisciplinary therapy for meningiomas.

  2019cites this paper
• Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

  2019cites this paper
• Titanium discs coated with 3,4-dihydroxy-l-phenylalanine promote osteogenic differentiation of human bone mesenchymal stem cells in vitro

  2019cites this paper
• An update on the CNS manifestations of neurofibromatosis type 2

  2019cites this paper
• Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting

  2019cites this paper
• Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy

  2019cites this paper
• Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms.

  2018cites this paper
• Emerging Medical Treatments for Meningioma in the Molecular Era

  2018cites this paper
• Advances in meningioma genetics: novel therapeutic opportunities

  2018cites this paper
• CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

  2018cites this paper
• LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy

  2018cites this paper
• The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma

  2018cites this paper
• New molecular targets in meningiomas: the present and the future

  2018cites this paper
• Regulatory network involving miRNAs and genes in serous ovarian carcinoma.

  2017cites this paper
• Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy

  2017cites this paper
• DNA methylation analysis for the treatment of meningiomas.

  2017cites this paper
• E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells

  2017cites this paper
• Systemic therapy for recurrent meningioma

  2016cites this paper
• EANO guidelines for the diagnosis and treatment of meningiomas.

  2016cites this paper
• Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1

  2016cites this paper
• Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors

  2015cites this paper
• FAK signaling in human cancer as a target for therapeutics.

  2015cites this paper
• FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth

  2015cites this paper
• The role of ?v integrins in human skin tissue homeostasis, wound healing and squamous cell carcinoma

  2015cites this paper
• Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway

  2015cites this paper
• FAK in cancer: mechanistic findings and clinical applications

  2014cites this paper